Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials

R. M. Savic, M. Weiner, W. R. Mackenzie, M. Engle, W. C. Whitworth, J. L. Johnson, P. Nsubuga, P. Nahid, N. V. Nguyen, C. A. Peloquin, K. E. Dooley, S. E. Dorman

Research output: Contribution to journalArticle

Abstract

Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure-response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculosis participating in treatment trials to compare rifapentine (n = 405) with rifampin (n = 252) as part of intensive-phase therapy. Population pharmacokinetic/pharmacodynamic analyses were performed with nonlinear mixed-effects modeling. Time to stable culture conversion of sputum to negative was determined in cultures obtained over 4 months of therapy. Rifapentine exposures were lower in participants who were coinfected with human immunodeficiency virus, black, male, or fasting when taking drug. Rifapentine exposure, large lung cavity size, and geographic region were independently associated with time to culture conversion in liquid media. Maximal treatment efficacy is likely achieved with rifapentine at 1,200 mg daily. Patients with large lung cavities appear less responsive to treatment, even at high rifapentine doses.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - 2017

Fingerprint

Phase II Clinical Trials
Pulmonary Tuberculoses
Pharmacokinetics
Lung
Rifampin
Sputum
Fasting
HIV
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Defining the optimal dose of rifapentine for pulmonary tuberculosis : Exposure-response relations from two phase II clinical trials. / Savic, R. M.; Weiner, M.; Mackenzie, W. R.; Engle, M.; Whitworth, W. C.; Johnson, J. L.; Nsubuga, P.; Nahid, P.; Nguyen, N. V.; Peloquin, C. A.; Dooley, K. E.; Dorman, S. E.

In: Clinical Pharmacology and Therapeutics, 2017.

Research output: Contribution to journalArticle

Savic, R. M.; Weiner, M.; Mackenzie, W. R.; Engle, M.; Whitworth, W. C.; Johnson, J. L.; Nsubuga, P.; Nahid, P.; Nguyen, N. V.; Peloquin, C. A.; Dooley, K. E.; Dorman, S. E. / Defining the optimal dose of rifapentine for pulmonary tuberculosis : Exposure-response relations from two phase II clinical trials.

In: Clinical Pharmacology and Therapeutics, 2017.

Research output: Contribution to journalArticle

@article{416940012e16472cb26e6d999a585862,
title = "Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials",
abstract = "Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure-response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculosis participating in treatment trials to compare rifapentine (n = 405) with rifampin (n = 252) as part of intensive-phase therapy. Population pharmacokinetic/pharmacodynamic analyses were performed with nonlinear mixed-effects modeling. Time to stable culture conversion of sputum to negative was determined in cultures obtained over 4 months of therapy. Rifapentine exposures were lower in participants who were coinfected with human immunodeficiency virus, black, male, or fasting when taking drug. Rifapentine exposure, large lung cavity size, and geographic region were independently associated with time to culture conversion in liquid media. Maximal treatment efficacy is likely achieved with rifapentine at 1,200 mg daily. Patients with large lung cavities appear less responsive to treatment, even at high rifapentine doses.",
author = "Savic, {R. M.} and M. Weiner and Mackenzie, {W. R.} and M. Engle and Whitworth, {W. C.} and Johnson, {J. L.} and P. Nsubuga and P. Nahid and Nguyen, {N. V.} and Peloquin, {C. A.} and Dooley, {K. E.} and Dorman, {S. E.}",
year = "2017",
doi = "10.1002/cpt.634",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Defining the optimal dose of rifapentine for pulmonary tuberculosis

T2 - Clinical Pharmacology and Therapeutics

AU - Savic,R. M.

AU - Weiner,M.

AU - Mackenzie,W. R.

AU - Engle,M.

AU - Whitworth,W. C.

AU - Johnson,J. L.

AU - Nsubuga,P.

AU - Nahid,P.

AU - Nguyen,N. V.

AU - Peloquin,C. A.

AU - Dooley,K. E.

AU - Dorman,S. E.

PY - 2017

Y1 - 2017

N2 - Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure-response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculosis participating in treatment trials to compare rifapentine (n = 405) with rifampin (n = 252) as part of intensive-phase therapy. Population pharmacokinetic/pharmacodynamic analyses were performed with nonlinear mixed-effects modeling. Time to stable culture conversion of sputum to negative was determined in cultures obtained over 4 months of therapy. Rifapentine exposures were lower in participants who were coinfected with human immunodeficiency virus, black, male, or fasting when taking drug. Rifapentine exposure, large lung cavity size, and geographic region were independently associated with time to culture conversion in liquid media. Maximal treatment efficacy is likely achieved with rifapentine at 1,200 mg daily. Patients with large lung cavities appear less responsive to treatment, even at high rifapentine doses.

AB - Rifapentine is a highly active antituberculosis antibiotic with treatment-shortening potential; however, exposure-response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculosis participating in treatment trials to compare rifapentine (n = 405) with rifampin (n = 252) as part of intensive-phase therapy. Population pharmacokinetic/pharmacodynamic analyses were performed with nonlinear mixed-effects modeling. Time to stable culture conversion of sputum to negative was determined in cultures obtained over 4 months of therapy. Rifapentine exposures were lower in participants who were coinfected with human immunodeficiency virus, black, male, or fasting when taking drug. Rifapentine exposure, large lung cavity size, and geographic region were independently associated with time to culture conversion in liquid media. Maximal treatment efficacy is likely achieved with rifapentine at 1,200 mg daily. Patients with large lung cavities appear less responsive to treatment, even at high rifapentine doses.

UR - http://www.scopus.com/inward/record.url?scp=85014095932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014095932&partnerID=8YFLogxK

U2 - 10.1002/cpt.634

DO - 10.1002/cpt.634

M3 - Article

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -